Delving into the Latest Updates on RACE-T (Rephimmune) with Synapse

Overview

Basic Info

Drug Type

Cell therapy

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases+ [2]

Active Indication

Esophageal CarcinomaMouth NeoplasmsStomach Cancer+ [1]

Inactive Indication-

Originator Organization

Rephimmune

Active Organization

Rephimmune

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

It previously had been proposed that the host-selective toxin of Helminthosporium maydis race T consists of a series of unusual linear (C(35) to C(45))polyketols, of equal toxicity on a weight or molar (10(-8)-10(-9)) basis. Previous laboratory synthesis of T-toxin analogs was limited to shorter (C(15) to C(26)) versions which possessed the requisite specificity for susceptible corn (Zea mays) but were less toxic on a weight or molar (10(-6)-10(-7)) basis. In the present study, a C(41) analog with four beta-ketol units spaced by CH(2) bridges as in native toxin has been synthesized. On a weight or molar basis, it is as effective as native toxin or its purified components in stimulating NADH oxidation of mitochondria from susceptible corn, thus providing firm evidence for the correctness of the proposed structures of T-toxin. Additional support derives from the observation that C(24) and C(26) analogs with -(CH(2))(4)- and -(CH(2))(6)- bridges between ketol groups are not as effective in stimulating NADH oxidation as are C(23) and C(25) analogs with the -(CH(2))(3)- and -(CH(2))(5)- bridges of native T-toxin.It was calculated that a single molecule of the C(41) analog is at least 300 times more effective in stimulating mitochondrial oxidation than a molecule of the C(23) or C(25) analogs. This emphasizes the importance of chain length for toxicity, perhaps through perturbation of membrane functions of mitochondria and/or chloroplasts.

100 Deals associated with RACE-T (Rephimmune)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Esophageal Carcinoma	Preclinical	Taiwan Province	Rephimmune	25 Sep 2024
Mouth Neoplasms	Preclinical	Taiwan Province	Rephimmune	25 Sep 2024
Stomach Cancer	Preclinical	Taiwan Province	Rephimmune	25 Sep 2024
Ovarian Cancer	Preclinical	Taiwan Province	Rephimmune	25 Sep 2024